Abstract. Irinotecan has been used in the first-line treatment of metastatic colorectal cancer. However, no clear predictive marker of irinotecan efficacy has been identified. It is controversial whether the response to irinotecan could be predicted by the expression level of topoisomerase-I, a direct target of irinotecan. The present study aimed to identify a feasible predictive marker of irinotecan efficacy. We hypothesized that the efficacy of SN38 (an active metabolite of irinotecan) is related to the cell proliferation and the phosphorylation status of RB in colorectal cancer cells. Indeed, the IC 50 of SN38 was positively correlated with the doubling time of each cell line (R 2 = 0.9315). Moreover, the phosphorylation level of RB was related to SN38 sensitivity. Consistent with the in vitro data, colorectal cancer tissues of irinotecan responders showed a significantly higher rate of phosphorylated RB (serine 780) expression using immunohistochemistry (P= 0.0006), although a generally used proliferative marker, Ki-67, showed no significance. Finally, we investigated whether the phosphorylation of RB plays a crucial role in the efficacy of irinotecan. To suppress the expression of phosphorylated RB, we performed the knockdown of CDKs, which are known to phosphorylate RB. Intriguingly, the knockdown of both CDK4 and CDK6, but not CDK2, allowed RB to become the most hypophosphorylated form and converted the SN38-sensitive cells to a resistant state. Taking together the above findings from in vitro and clinical research, the immunohistochemistry of phosphorylated RB protein might be feasible to predict the irinotecan efficacy of colorectal cancer in clinical practice.
Introduction
Irinotecan has been used for around two decades in chemotherapies against several advanced cancers. Especially in the first-line treatment of metastatic colorectal cancers, irinotecan has been one of the mainstay drugs, with longer progressionfree survival and overall survival (1-3). However, no clear predictive marker of irinotecan efficacy has been identified, despite its widespread use.
Irinotecan directly inhibits topoisomerase I (Top I) to prevent re-ligation of the nicked DNA strand during DNA replication (4, 5) , and then it has been suggested that a high expression level of Top I correlates with its efficacy (6) . For instance, in a large prospective study, the UK MRC FOCUS trial for advanced colorectal cancer patients, moderate or high Top I expression was associated with longer survival in patients treated with irinotecan in addition to 5-fluorouracil (7) . Conversely, in the CAIRO study, in which advanced colorectal cancer patients were also prospectively interrogated, no association was found between the response to irinotecan and Top I expression (8, 9) . Additionally, another report mentioned that the cells that acquired resistance to SN38 (an active metabolite of irinotecan) maintained Top I expression levels (10) . Therefore, Top I expression is supposed to be insufficient for the prediction of irinotecan efficacy clinically.
On the contrary, it has been supposed that cytotoxic chemotherapies show susceptibility in highly proliferative cells. Actually, a recent meta-analysis study suggested that the response to Top I inhibitors is associated with the cell growth rate (11) . One of the critical points in the regulation of cellular proliferation is the G1/S transition, which is controlled by the phosphorylation status of RB protein. In malignant tumor cells, RB inactivation with its phosphorylation leads to cellular proliferation.
Considering the above, we investigated whether the efficacy of SN38 is related to the cell proliferation rate and the phosphorylation status of RB in colorectal cancer cells. We then validated the relationship between the levels of phosphorylated RB and the responses to irinotecan in clinical samples Cell cycle analysis. Cells were exposed to SN38 at the indicated concentrations for 72 h and then harvested. They were permeabilized with 0.1% Triton X-100 and the nuclei were stained with propidium iodide. The DNA contents were measured using a FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) and analyzed with ModFit LT (Verity Software House, Topsham, ME, USA). The patient eligibility criteria were: no synchronous tumors, and not having received a preoperative chemotherapy or a radiation therapy. All the patients gave their written informed consent. Relevant clinicopathological and survival data were obtained from the hospital database. After operations, 22 patients underwent second-or third-line chemotherapies with irinotecan, which targeted metastasis or recurrence, and only 1 patient underwent treatment with irinotecan as the first-line therapy. The following treatments with irinotecan were applied: FOLF I R I (5-F U+leucovor in+i r ino teca n), FOLFIRI+BEV (FOLFIRI+bevacizumab), FOLFIRI +C-mab (FOLFIRI+cetuximab), FOLFIRI+P-mab (FOLFIRI +panitu-mumab), CPT-11+C-mab (irinotecan+cetuximab), IRIS (irinotecan+S-1), and IRIS+BEV (IRIS+bevacizumab). Computed tomography (CT) was performed after the treatment with irinotecan for approximately 5 courses. The curative effects were evaluated by RECIST v1.1 (12) , referring to the pictures of CT. A total of 5 patients were classified with partial response (PR), 10 with stable disease (SD) and 8 with progressive disease (PD). We classified PR patients into a responder group, and SD and PD patients into a non-responder group. Disease staging was principally based on The Union for International Cancer Control/TNM Classification of Malignant Tumours (7th edition) (13) .
Immunohistochemistry. Paraffin sections (3 mm thick) of tumor tissue were subjected to immunohistochemical staining for phosphorylated RB (serine 780) and Ki-67 (MIB-1) using the avidin-biotin-peroxidase method. Briefly, paraffin sections were dewaxed in xylene and hydrated through a graded series of alcohol. Endogenous peroxidase activity was quenched by incubating the sections for 30 min in 0.3% H 2 O 2 . The sections were then treated with a protein blocker and incubated with antibodies. Sections were incubated for 1 h at 37˚C with a mouse anti-RB (phospho S780) antibody (Abcam), and were incubated for 1 h at room temperature with Ki-67 (Santa Cruz Biotechnology). The avidin-biotin-peroxidase complex system (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA, USA) was used for color development with diaminobenzidine tetrahydrochloride. The sections were counterstained with hematoxylin. Finally, the sections were dehydrated through a graded series of alcohol, cleared in xylene and mounted. Tumor cells with immunohistochemical expression in the cytoplasm were counted as phosphorylated RB-positive. For scoring the phosphorylated RB expression, the percentage of the total cell population that expressed phosphorylated RB (serine 780) was evaluated for each case. The labeling index (LI) of immunohistochemistry for Ki-67 was determined by counting positive tumor cells in the most intensely stained region. Severely keratinized portions in the nest of colorectal cancers were excluded.
Statistical analysis. Significance was assessed by Student's t-test or Mann-Whitney U test for comparisons between two groups. Fisher's exact test was performed to investigate the correlations between clinicopathological parameters and phosphorylated RB expression level. Differences were considered significant when the P-value was <0.05.
Results
The sensitivity to SN38 is inversely correlated with the doubling time of cells. We examined each IC 50 value of SN38 using eight human colorectal cancer cells as shown in Table I . The HCT116, LIM1215, SW480 and SW620 cells were sensitive to SN38, with IC 50 values of <4 nM. The CCK-81, CoCM-1, SW837 and Caco-2 cells were resistant to SN38, with IC 50 values of >80 nM. We found no association between the sensitivity to SN38 and the expression level of Top I in these cell lines (Fig. 1A) .
We next measured the doubling times of the cell lines (Table I ) and plotted them against the IC 50 values of SN38. As shown in Fig. 1B , the doubling times of the cell lines and the IC 50 values of SN38 showed an appreciable positive correlation (R 2 = 0.9315) (Fig. 1B) . These results indicate that highly proliferative cells are more sensitive to SN38.
Phosphorylation status of RB is relevant to the sensitivity to SN38 of cell lines. We then performed western blotting to detect the phosphorylated RB of each cell line, which is unable to bind to the transcription factor E2F, resulting in proliferation of the cells. The SN38-sensitive cell lines showed hyperphosphorylation of RB without alteration of the total amount of RB protein, while the resistant cell lines showed hypophosphorylation of RB, with the exception of the phosphorylated RB at serines 807/811 in Caco-2 cells (Fig. 2A) . Caco-2 cells are known to express BCRP (breast cancer resistance protein) (14) , which transports SN38 (15) . Indeed, we confirmed that only Caco-2 cells expressed BCRP among these cell lines (Fig. 2B) , suggesting that these cells show resistance to SN38 despite hyperphosphorylation of RB at serines 807/ 811.
Taken together, these results suggest that the phosphorylation status of RB could predict the efficacy of irinotecan.
Phosphorylation status of RB protein detected by immunohistochemistry may predict the response to irinotecan in patient specimens. We then examined whether the expression levels of phosphorylated RB could predict the response to irinotecan in the patient specimens. The 23 patients with colorectal cancers were classified into responder and non-responder groups, according to the responses to the treatments including irinotecan, as described in Materials and methods (Table II) . The patient characteristics of the irinotecan responders and non-responders are shown in Table III . There was no significant difference in the overall survival between the responders and non-responders (data not shown). Next, we analyzed the relationships between various clinicopathological parameters and the phosphorylated RB expression levels determined by immunohistochemistry (IHC). Representative phosphorylated RB expression levels of the tumors are shown in Fig. 3A . We then evaluated the phosphorylated RB expression levels in 23 samples, as described in Materials and methods, and defined the appropriate IHC cut-off values of stained tumor cells. As a consequence, we found that the colorectal cancer tissues of irinotecan responders showed a significantly higher positivity rate of the phosphorylated RB (serine 780) at a cut-off value of 25% (P=0.0006; Table IV) , while the labeling index (LI) of Ki-67 (MIB-1), which is clinically used as a diagnostic marker of tumor proliferation, showed no statistically significant difference between responders and non-responders ( Fig. 3B and C). Taking these findings together, IHC of the phosphorylated RB (serine 780) in tumor might be useful to predict the response to irinotecan, rather than Ki-67. 
Knockdown of both CDK4 and CDK6 reduces G2/M accumulation induced by SN38 with RB dephosphorylation.
We next investigated whether the phosphorylation of RB plays a crucial role in the efficacy of irinotecan. We performed the knockdown of CDKs, which are well known to phosphorylate RB protein, to suppress the expression of phosphorylated RB. CDK2, CDK4, CDK6 and CDK4/6 were silenced by siRNA in the SN38-sensitive cell lines (Fig. 4A) . RB protein was converted to the unphosphorylated form most strikingly after the simultaneous knockdown of CDK4 and CDK6 in SW620 and SW480 cells, while the knockdown of CDK2 did not affect the phosphorylation status of RB protein (Fig. 4B) . SN38 treatment for 72 h induced dose-dependent G2/M arrest in SW620 and SW480 cells (Fig. 4C) . However, the G2/M arrest induced by 5 nM SN38 for 72 h in these cells was restored most by siCDK4/6 (Fig. 4D) , which most markedly reduced the level of the phosphorylated form of RB protein (Fig. 4B) .
The sensitivity to SN38 is dampened by the knockdown of both CDK4 and CDK6. Finally, we investigated whether CDK4/6 activities affected the sensitivity to SN38. As shown in Fig. 5A , SW620 cells exhibited resistance to SN38 after both CDK4 and CDK6 were silenced. The transfection of siCDK4/6 gave an increased median IC 50 value of SN38 of 58.4 nM, while that of a negative control gave a median IC 50 value of 1.4 nM (Fig. 5B) . Thus, the sensitivity to irinotecan might be governed by the activities of CDK4/6 in colorectal cancer.
Discussion
We showed for the first time that the efficacy of irinotecan could be predicted by phosphorylated RB expression, which is known to be crucial for G1/S progression and cell proliferation. We proved the positive correlation between the phosphorylated status of RB and the efficacy of SN38 in colorectal cancer cell lines. In line with the in vitro study, our clinical retrospective study demonstrated that the positivity rate of the phosphorylated RB (serine 780) was significantly higher in colorectal cancer tissues of irinotecan responders.
The phosphorylation of RB protein endows the cells with the ability to pass through the restriction point at the late G1 phase, enabling the cell cycle to progress (16) . In most cancer cells, RB protein is hyperphosphorylated, resulting in uncontrolled cell proliferation (17) (18) (19) (20) . Indeed, colorectal cancer tissues were shown to express the phosphorylated RB at a high level compared with adenomas or normal colonic mucosa (21) . Thus, RB phosphorylation is considered to play a crucial role in colorectal cancer progression.
Irinotecan targets proliferative cells and works during S phase with the inhibition of Top I (4, 5, (22) (23) (24) . In our clinical study, colorectal cancer tissues of irinotecan responders showed a significantly higher positivity rate of phosphorylated RB at serine 780, rather than that of Ki-67 clinically used as a proliferative marker. The expression of Ki-67 increases in S phase but reaches a maximum in M phase (25) (26) (27) , suggesting its efficacy as an M-phase marker. On the contrary, the phosphorylation of RB occurs at the end of G1 phase, with cells progressing to S phase (28, 29) , suggesting its efficacy as an S-phase marker. Given that irinotecan attacks cancer cells in S phase, it is rational that the phosphorylated RB affects the susceptibility to irinotecan, rather than Ki-67. RB protein is phosphorylated by CDKs, resulting in cell cycle progression. However, there seems to be a difference in terms of which kinds of CDKs are essential for the proliferation of cancer cells, depending on the cellular context (30) . For instance, CDK2 activity was shown to be related to the prognosis of breast cancer (31, 32) and renal cell carcinoma (33) , while CDK4 contributed to cell proliferation in colorectal cancer (34) and non-small cell lung cancer (35) . We performed knockdown experiments of CDK2, CDK4, CDK6 and CDK4/6 to convert the phosphorylated RB to the unphosphorylated form. Of particular interest, our data showed that silencing of both CDK4 and CDK6, but not CDK2, led RB to adopt the most hypophosphorylated form (Fig. 4B ) and rendered cells resistant to SN38 (Fig. 5) , suggesting that CDK4/6 activities Table IV . Associations between the clinicopathological characteristics of colorectal cancer patients and phosphorylated RB (serine 780) (cut-off value, 25%). are indispensable for the proliferation of colorectal cancer cells. Thus, the role of CDK4 and CDK6 could be crucial in not only RB phosphorylation and proliferation of colon cancer cells but also sensitivity to irinotecan.
In conclusion, we found that the phosphorylation status of RB protein could be a novel and promising predictive marker of irinotecan efficacy for colorectal cancer, based on the rationale that cells with highly phosphorylated RB would be more exposed to irinotecan through proceeding to S phase. In the chemotherapies for colorectal cancer, which have been more complicated and diverse, it has become increasingly necessary to stratify the treatment responders. Now we are planning larger cohort studies to examine whether this novel predictive marker of irinotecan efficacy could improve the outcome of colorectal cancer.
